

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, March 24, 2023

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Heather Preuss, MD	
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	
Mikel Holland, MD		Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard, DSS Staff	
Lenny Petrik, PharmD		Sarah Aker, DSS Staff	

Administrative Business

Darger called the meeting to order at 1:03 pm. The minutes of the December meeting were presented. Ladwig made a motion to approve. Baack seconded the motion. The motion was unanimously approved.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from October 1, 2022, to December 31, 2022. A total of 1,968 PAs were reviewed of which 100 requests (5.1%) were received via telephone and 1,297 requests (65.9%) were received via fax, and 571 (29%) were reviewed via electronically. There was a 6.3% increase of PAs received compared to the previous quarter. Under the Top 5 therapeutic classes for PAs, Baack inquired on the sertraline PAs listed next to the Antidepressants. An in-depth review was requested.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from October 1, 2022, to December 31, 2022. The top five therapeutic classes based on paid amount were atypical antipsychotics, skin and mucous membrane agents, disease-modifying anti-rheumatic agents, hemostatics, and amphetamines. These top 15 therapeutic classes comprise 25.82 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.23% of total claims. There was a notable increase in antibiotic prescriptions which corresponded with the 2022-2023 flu season peaking early. Baack commented on seeing more patients using Xolair at her practice. Of interest, Darger commented on the new biosimilar approved in January.

Darger inquired if there was any public testimony. There were none.

Old Business

Fleqsuvy & baclofen review

The committee reviewed Fleqsuvy and baclofen utilization. Fleqsuvy was reviewed at the June P&T meeting the previous year. Committee had requested to review Fleqsuvy utilization when utilization increased. Darger commented that Fleqsuvy suspension is in a concentrated form compared to the solution. Baack said the liquid form is convenient for older children with a g-tube. After further discussion, committee requested to review Fleqsuvy and baclofen next year with a breakdown in quantity and cost per dose.

Selgentis & tramadol review

The committee reviewed Selgentis and tramadol utilization. Seglentis was reviewed at the September P&T meeting the previous year. After discussion, committee was satisfied with the utilization and only asked to bring it back if utilization increased significantly.

Vuity & pilocarpine review

The committee reviewed Vuity and pilocarpine utilization. Vuity was reviewed at the March P&T meeting the previous year. After reviewing utilization over three quarters, Ladwig commented his surprise that Vuity didn't take off as expected but expressed the need for continual monitoring and to review next year.

Darger inquired if there was any public testimony. There were none.

Opioid update

The committee reviewed 4Q2022 opioid outcomes compared to previous quarters from the opioid initiatives. There was a decrease in opioid utilization and utilizers during 4Q2022 even with an increase in total eligibility and utilizers. Darger inquired if there was any public testimony. There was none. Darger commented the initiatives that are continuing to work. Ladwig concurred.

New Business

Dermatological PA review

Baack expressed the need to review the Dermatological PAs at the last meeting concentrating on diagnosis of atopic dermatitis, psoriasis, rosacea, and topical acne treatments. The committee reviewed the Opzelura PA reviews and utilization which compared the first half of 2022 to second half of 2022. Baack questioned if Eucrisa should be on PA. An in-depth review of Eucrisa utilization including age breakdown, diagnosis of atopic dermatitis, length of therapy, taxonomy of prescribers, and other state PA criteria on Eucrisa were requested.

The committee reviewed other drugs used for psoriasis and atopic dermatitis. After discussion, Baack motioned to add PA to Vtama to indication. Ladwig seconded the motion. Darger inquired if there was any public testimony. There was none. The motion was approved unanimously.

The committee reviewed rosacea and topical acne PA reviews and utilization. After discussion, Baack motioned to remove generics such as adapalene/Differin cream, adapalene /Differin gel, adapalene-benzoyl gel, benzoyl-erythromycin gel, clindamycin-benzoyl peroxide gel, tretinoin microsphere gel/pump, tazarotene cream from the topical acne PA. Oehlke seconded the motion. Darger inquired if there was any public testimony. There was none. The motion was approved unanimously.

The committee reviewed the rosacea PA reviews and utilization. After discussion, Baack motioned to remove metronidazole gel 1% from the rosacea PA criteria and add Winlevi cream to it. Ladwig seconded the motion. Darger inquired if there was any public testimony. There was none. The motion was approved unanimously.

Mupirocin trend

The committee reviewed an in-depth analysis of mupirocin utilization at Darger's request since it had climbed to the top 50 drug based on number of claims. Most of the utilization was concentrated at the two years age span. Baack commented on its use for impetigo. The committee was satisfied with the review.

Epinephrine trend

The committee reviewed an in-depth review of epinephrine utilization since it had climbed the top 50 drugs by paid amount. AUVI-Q-Q utilization was noted during January 2023. Both Van Gilder and Oehlke provided information that AUVI-Q is a guided epinephrine injection that provides audio and visual cues that may be useful especially for children. Darger and Ladwig commented on adding AUVI-Q to PA. After discussion, it was requested to bring AUVI-Q back to the next meeting; providing utilization and break down on age including other state's PA criteria.

Darger inquired if there was any public testimony. There was none.

Review PA forms & criteria

The committee reviewed the PA forms and criteria. Jockheck provided an update on the Hepatitis C PA criteria. Effective April 1, 2023, the sobriety requirement, metavir score, fibrocan score, APRI score, and documentation of severe manifestations of hepatitis C will be removed.

Jockheck also mentioned the drug Makena will be removed from the market. Darger commented lindane and Sklice are no longer available on the market. Baack said there are new asthma guidelines and the need to review asthma drugs as a class. She will invite a pulmonologist to the June meeting. Ladwig commented on the GLP-1 PA criteria. The committee discussed what qualifies for type 2 diabetes. Ladwig said Brisdelle is no longer available as brand. Jockheck said next time the PA forms and criteria are reviewed, the number of requests for each PA will also be provided.

Baack motioned to accept the PAs with few changes discussed. Ladwig seconded the motion. Darger inquired if there was any public testimony. There were none. The motion was approved unanimously.

Xelstrym

Xelstrym clinical information was presented for review. After discussion, committee requested to review if utilization increased in volume. Darger inquired if there was any public testimony. There were none.

Jockheck provided an update from Sam Moon from the Department of Medical Services on follow up care for children prescribed ADHD medications and metabolic monitoring for children and adolescents on antipsychotics. The review at previous meetings had seem to show that patients were not receiving metabolic check-ups, but many are receiving it. However, there is still room for improvement, but not as bad as initially thought.

Darger announced his retirement from the P&T Committee after serving 18 years. December will be his last meeting. Van Gilder accepted the role of chairman starting in 2024.

Adjournment

The next meeting scheduled on June 9, 2023. The September meeting is tentatively scheduled for September 8, 2023. The December meeting is tentatively scheduled for December 8, 2023. Ladwig made a motion to adjourn the meeting and Baack seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:52 pm CT.